Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0166

Scientific exchange · Dr. Ingrid Dubois

13 Mar 2026 · In person · Dr. Ingrid Dubois, Policlinico Gemelli · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0166—

Capture insight from this engagement

Location: Policlinico Gemelli
Therapeutic area: Neurology
Country: Italy
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Medication-overuse headache

Scientific content used

Chronic migraine scientific platform

Questions raised

Any data in patients with medication-overuse headache?
What is the persistence rate at 18 months in real-world cohorts?

Notes

Scientific exchange with general neurologist at Policlinico Gemelli. Discussed medication-overuse headache.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0166

Audit history (0)

All create, update and approval events for this record

No audit events in sample data